Venus Remedies Secures Coveted UNICEF Approval for Global Impact
Venus Remedies Limited, a leading pharmaceutical company with a global footprint, is proud to announce its recent attainment of Good Manufacturing Practices (GMP) approval from the United Nations Children's Fund (UNICEF). This approval signifies a significant milestone for the company, highlighting its unwavering commitment to delivering top-tier pharmaceutical solutions worldwide.
UNICEF, renowned for its humanitarian and developmental aid to children worldwide, is one of the most widely known and visible social welfare entities globally. The agency's stringent GMP approval process sets a benchmark for quality and safety in pharmaceutical production, and Venus Remedies' successful accreditation underscores its dedication to meeting these rigorous standards.
Saransh Chaundhary, CEO of Venus Medicine Research Centre, expressed his enthusiasm, stating, "We are immensely proud to receive GMP approval from UNICEF, which further validates our relentless pursuit of excellence in pharmaceutical manufacturing. This achievement opens doors for us to contribute significantly to global healthcare initiatives and make a positive impact on communities worldwide."
GMP approval from UNICEF grants Venus Remedies access to participate in tenders for the supply of essential medications, positioning the company to address critical healthcare needs in regions facing challenges. This endorsement aligns perfectly with Venus Remedies' mission to enhance access to quality healthcare globally.
The approval from UNICEF enables Venus Remedies to leverage its expertise in pharmaceutical production to contribute to global healthcare efforts effectively. With this accreditation, the company can now participate in tenders for the supply of Cephalosporin dry powder for injection, further expanding its reach and impact in the healthcare sector.
Venus Remedies Limited's manufacturing unit 2, located in Baddi, Himachal Pradesh, India, has been recommended for the supply of Cephalosporin dry powder for injection to UNICEF. The company's commitment to maintaining the highest standards of manufacturing excellence, as evidenced by its compliance with WHO Technical Report Series 986, reinforces its position as a trusted partner in global healthcare supply chains.
With this approval, Venus Remedies continues to strengthen its international presence, building upon its extensive portfolio of certifications from regulatory bodies worldwide. The company remains steadfast in its commitment to delivering innovative and high-quality pharmaceutical solutions to improve healthcare outcomes globally.
